A controversial new drug for ALS could add months to patients' lives – if it actually works
of just 137 patients. Results suggested the drug might extend patients' lives by five to six months, or more.
"I totally understand why people would be trying to figure out a way to get this to patients," he says."There's just a general concern out there that maybe the trial is wrong." The second vote came after Dr. Billy Dunn, director of the FDA's Office of Neuroscience, encouraged the committee to exercise"flexibility" when considering a drug that might help people facing certain death.A negative result from that study would be a major blow to Amylyx and ALS patients.
Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
Carlos Pacheco, Suffering From ALS, Posts His Final Comics CoverCarlos Pacheco is a Spanish comic book creator, best known in the US for comic books such as Avengers Forever, X-Men, Superman, Fantastic Four, Green
Weiterlesen »
ALS Drug Gets FDA Panel Thumbs Up After Rare Second LookAn FDA advisory panel reversed its March decision to reject a novel drug for ALS, citing persuasive new evidence and clinician support.
Weiterlesen »
ALS drug gets FDA approval despite uncertainty about effectivenessThe oral medication can be taken as a standalone therapy or with other treatments, according to the company, and it has been shown to slow disease progression.
Weiterlesen »
ALS drug wins FDA approval despite questionable dataThe drug, Relyvrio, is the third U.S.-approved medicine for amyotrophic lateral sclerosis, or ALS, which destroys nerve cells needed for basic functions like walking, talking and swallowing.
Weiterlesen »
ALS drug gets FDA approval despite uncertainty about effectivenessThe oral medication can be taken as a standalone therapy or with other treatments, according to the company, and it has been shown to slow disease progression.
Weiterlesen »
ALS drug wins FDA approval despite questionable dataWASHINGTON (AP) — A much-debated drug for Lou Gehrig’s disease won U.S. approval Thursday, a long-sought victory for patients that is likely to renew questions about the scientific rigor behind government reviews of experimental medicines.
Weiterlesen »